GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » EPS (Diluted)

CTNM (Contineum Therapeutics) EPS (Diluted) : $-0.06 (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics EPS (Diluted)?

Contineum Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was $-0.39. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.06.

Contineum Therapeutics's EPS (Basic) for the three months ended in Jun. 2024 was $-0.39. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.06.

Contineum Therapeutics's EPS without NRI for the three months ended in Jun. 2024 was $-0.39. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.22.

During the past 12 months, Contineum Therapeutics's average EPS without NRIGrowth Rate was -183.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Contineum Therapeutics EPS (Diluted) Historical Data

The historical data trend for Contineum Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics EPS (Diluted) Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EPS (Diluted)
-1.74 -1.46 1.12

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only 0.17 0.92 -0.29 -0.31 -0.39

Competitive Comparison of Contineum Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Contineum Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Contineum Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's PE Ratio falls into.



Contineum Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Contineum Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(22.72-0)/17.761
=1.28

Contineum Therapeutics's Diluted EPS for the quarter that ended in Jun. 2024 is calculated as

Diluted EPS (Q: Jun. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-9.009-0)/23.356
=-0.39

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Contineum Therapeutics  (NAS:CTNM) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Contineum Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.